TheranosticTrials.org

Clinical Trial · NCT01755650

Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Overview

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.

Sponsor

Peter MacCallum Cancer Centre

Phase

Early Phase 1

Contacts

Ben Solomon (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01755650

Drug / Compound

FPM

Isotope(s):
Target(s):
  • Amino Acid Transport

Eligibility

Inclusion

  • * Written informed consent obtained prior to any protocol-specific procedures
  • Life expectancy \>/= 3 months
  • At least one site of active malignancy, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
  • Male and female patients with histologically confirmed squamous cell carcinoma
  • Age \>/= 18 years

Exclusion

  • Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent
  • Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study
  • Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F FPM PET/CT scan
  • * Pregnant or breastfeeding females